Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

G. O’Brien, Stephen; Guilhot, François; A. Larson, Richard; Gathmann, Insa; Baccarani, Michele; Cervantes, Francisco; J. Cornelissen, Jan; Fischer, Thomas; Hochhaus, Andreas; P. Hughes, Timothy; Lechner, Klaus; Lanng Nielsen, Johan; Rousselot, Philippe; Reiffers, Josy; Saglio, Giuseppe; D. Shepherd, John; Simonsson, Bengt; Gratwohl, Aloïs; M. Goldman, John; M. Kantarjian, Hagop; Taylor, Kerry; Verhoef, Gregor; E. Bolton, Ann; Capdeville, Renaud; Druker, Brian

doi:10.1056/nejmoa022457

Public

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Published in New England Journal of Medicine • Mar 13, 2003

Authors:

Stephen G. O’Brien

François Guilhot

Richard A. Larson

Abstract

BACKGROUND: Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose...

Subject

Medicine

Imatinib

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!